- Home
- APLT vs LVTX Comparison
APLT vs LVTX Comparison
Compare APLT & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- LVTX
- Stock Information
- Founded
- APLT 2016
- LVTX 2016
- Country
- APLT United States
- LVTX Netherlands
- Employees
- APLT N/A
- LVTX N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- LVTX Health Care
- Exchange
- APLT Nasdaq
- LVTX Nasdaq
- Market Cap
- APLT 37.5M
- LVTX 33.9M
- IPO Year
- APLT 2019
- LVTX 2021
- Fundamental
- Price
- APLT $0.35
- LVTX $1.31
- Analyst Decision
- APLT Buy
- LVTX Hold
- Analyst Count
- APLT 7
- LVTX 3
- Target Price
- APLT $6.10
- LVTX $1.75
- AVG Volume (30 Days)
- APLT 1.4M
- LVTX 39.1K
- Earning Date
- APLT 08-06-2025
- LVTX 08-19-2025
- Dividend Yield
- APLT N/A
- LVTX N/A
- EPS Growth
- APLT N/A
- LVTX N/A
- EPS
- APLT N/A
- LVTX N/A
- Revenue
- APLT $265,000.00
- LVTX $4,990,000.00
- Revenue This Year
- APLT $1,768.13
- LVTX N/A
- Revenue Next Year
- APLT $292.85
- LVTX N/A
- P/E Ratio
- APLT N/A
- LVTX N/A
- Revenue Growth
- APLT N/A
- LVTX N/A
- 52 Week Low
- APLT $0.30
- LVTX $0.85
- 52 Week High
- APLT $10.62
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- APLT 42.17
- LVTX 51.02
- Support Level
- APLT $0.34
- LVTX $1.28
- Resistance Level
- APLT $0.38
- LVTX $1.40
- Average True Range (ATR)
- APLT 0.02
- LVTX 0.05
- MACD
- APLT -0.00
- LVTX -0.00
- Stochastic Oscillator
- APLT 7.14
- LVTX 52.63
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.